A new combination therapy regimen shows promising results for prostate cancer
The combination of two oral medications has shown positive results in people with prostate cancer, whose disease has spread to other parts of the body. Compared with XTANDI plus placebo, the investigatory combination of TALZENNA and XTANDI demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Materials provided by Huntsman Cancer Institute. Note: Content may be edited for style and length.
Source link aaaaa
